[1] 中国抗癌协会乳腺癌专业委员会.中国乳腺癌筛查与早期诊断指南[J].中国癌症杂志,2022,32(4):363-372.
[2] 中华人民共和国国家卫生健康委员会.乳腺癌诊疗指南(2022年版)[EB/OL].[2022-04-11].http://www.nhc.gov.cn/yzygj/s2911/202204/a0e67177df1f439898683e1333957c74.shtml.
[3] TUTT A N J,GARBER J E,KAUFMAN B,et al.Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer[J].N Engl J Med,2021,384:2394-2405.
[4] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2021[M].北京:人民卫生出版社,2021:84-85.
[5] ROBSON M,TUNG N,CONTE P,et al.OlympiAD final overall survival and tolerability results:olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J].Ann Oncol,2019,30(4):558-566.
[6] ROBSON M,IM S A,SENKUS E,et al.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J].N Engl J Med,2017,377(6):523-533.
[7] PARACHA N,THURESSON P O,MORENO S G,et al.Health state utility values in locally advanced and metastatic breast cancer by treatment line:a systematic review[J].Expert Rev Pharmacoecon Outcomes Res,2016,165:549-559.
[8] LIU X Y,LANG Y T,LIAO Y H,et al.Atezolizumab plus chemotherapy vs.chemotherapy in advanced or metastatic triple-negative breast cancer:a cost-effectiveness analysis[J].Front Public Health,2021,9:756899.
[9] MARTIKAINEN J A,KIVIOJA A,HALLINEN T,et al.Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme[J].Pharmacoeconomics,2005,23(8):803-815.
[10] MILLER D K,HOMAN S M.Determining transition probabilities:confusion and suggestions[J].Med Decis Making,1994,14(1):52-58.
[11] 国家卫生健康委员会.中国居民营养与慢性病状况报告(2020年)[J].营养学报,2020,42(6):521.
[12] 刘国恩.中国药物经济学评价指南[M].北京:中国市场出版社有限公司,2020:34-46.
[13] 国家统计局.中华人民共和国 2021 年国民经济和社会发展统计公报[N].人民日报,2022-3-1(10).
[14] BRIGGS A H,WEINSTEIN M C,FENWICK E A,et al.Model parameter estimation and uncertainty analysis:a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6[J].Med Decis Making,2012,32(5):722-732.
[15] 朱娟,王乐,何世娇,等.中国乳腺癌健康效用值研究的系统评价[J].中国循证医学杂志,2017,17(9):1066-1071. |